SlideShare ist ein Scribd-Unternehmen logo
1 von 19
Bakry Al-kafMatteoNebioloVietti
Index About Merck. Merck’s Programs. Today’s Merck. The Global Pharmaceutical Industry. Financial information.
 About Merck global research-driven pharmaceutical company Originally founded in 1668 in Germany. Established in 1891 in U.S.A. Its commitment to help all patients obtain access to the Merck medicines they need.
Merck Programs Merck Patient Assistance Program. Free medicines. 1.5 million prescriptions. Medicines for chronic conditions. Merck Prescription Discount Program.  For the uninsured.  Saving of 15% to 20% off.  Easy to access. Merck's HIV research Program. Merck Medical Outreach Program.
Merck's Contributionin Haiti Relief Efforts In response to this disaster. Initial contribution. Donating needed medicines. Participation on the ground.
Our Products Vaccines Prescription Products Animal Health Consumer Products
From Laboratoryto Pharmacy Shelf Drug Discovery Preclinical Testing Investigational New Drug (IND) Application Clinical Trials Phase I Phase II Phase III Phase IV Approval Review
The Pharmaceutical Industry Value Chain
Current Strategies Merger with Schering-Plough. Job cuts follows the merger. Biotech medications. acquisition. ( Merck buys Avecia) Diversification. Innovation.
Risks Vioxx lawsuits issue. Withdrawn in 2004. 4 billion Settlement agreement charge. Certain of the Company’s products are going to lose patent protection.
Competitors    COMPANY	                  COUNTRY         TOTAL REV  M USD        % R&D Switzerland               53,324          -            13%                                                       USA                         48,371          –        1 6%  BayerGermany                     44,2             -            4%  GlaxoSmithKline                       United Kingdom  -       42,813          -            15%  Johnson and Johnson                USA                            37,02          -            14%  Sanofi-Aventis                            France                       35,645          -           16%  Switzerland                  33,547        -           16%  AstraZeneca                           UK/Sweden                   26,475        -           15%  Merck & Co.                                 USA                           22,636        -            21%
Competitors
Competitors
Financial Information Annual Sales ($m)
Financial Information Material and Production Cost ($m)
Financial Information Net income as a % of sales
Current Strategies ,[object Object]
Despite critics referring to Robert Gallo.
We won’t follow Italian/European HIV strategy even if we could  (2007).

Weitere ähnliche Inhalte

Was ist angesagt?

Pfizer strategy for internationalization
Pfizer strategy for internationalizationPfizer strategy for internationalization
Pfizer strategy for internationalizationAamir chouhan
 
Novartis - Strategy Memo
Novartis - Strategy MemoNovartis - Strategy Memo
Novartis - Strategy MemoRheetam Mitra
 
Strategic Management presentation for a Pharmaceutical Industry
Strategic Management presentation for a Pharmaceutical IndustryStrategic Management presentation for a Pharmaceutical Industry
Strategic Management presentation for a Pharmaceutical IndustryEngr. Carlo Senica, MBA, CPSM
 
cipla and sun pharma
cipla and sun pharmacipla and sun pharma
cipla and sun pharmaAkash Gawande
 
Pharmaceutical Marketing Strategy
Pharmaceutical Marketing StrategyPharmaceutical Marketing Strategy
Pharmaceutical Marketing StrategyAwais e Siraj
 
Brand plan for 2010 glycomet (us vitamin) - mitesh shah
Brand plan for 2010   glycomet (us vitamin) - mitesh shahBrand plan for 2010   glycomet (us vitamin) - mitesh shah
Brand plan for 2010 glycomet (us vitamin) - mitesh shahMitesh Shah
 
Glaxosmithkline portfolio
Glaxosmithkline portfolioGlaxosmithkline portfolio
Glaxosmithkline portfolioVinay Desai
 
Competitive advantage and strategy formulation process
Competitive advantage and strategy formulation processCompetitive advantage and strategy formulation process
Competitive advantage and strategy formulation processvitusmaren
 
Merck: Global Health and Access to Medicines
Merck: Global Health and Access to  MedicinesMerck: Global Health and Access to  Medicines
Merck: Global Health and Access to MedicinesTony Sebastian
 
Pfizer company analysis
Pfizer company analysisPfizer company analysis
Pfizer company analysisnero2.0
 
Supply Chain Management Glenmark Pharma
Supply Chain Management Glenmark PharmaSupply Chain Management Glenmark Pharma
Supply Chain Management Glenmark PharmaAbhishek Dhamankar
 
Pharma Plan Presentation Powerpoint
Pharma Plan Presentation PowerpointPharma Plan Presentation Powerpoint
Pharma Plan Presentation Powerpointwaschmaschine
 
Case Study Analysis on GlaxoSmithkline
Case Study Analysis on GlaxoSmithklineCase Study Analysis on GlaxoSmithkline
Case Study Analysis on GlaxoSmithklineAanchal Saxena
 
Glaxo smith-kline-presentation
Glaxo smith-kline-presentationGlaxo smith-kline-presentation
Glaxo smith-kline-presentationHarram Aneeqa
 

Was ist angesagt? (20)

Pfizer strategy for internationalization
Pfizer strategy for internationalizationPfizer strategy for internationalization
Pfizer strategy for internationalization
 
Case study on merck
Case study on merckCase study on merck
Case study on merck
 
Novartis - Strategy Memo
Novartis - Strategy MemoNovartis - Strategy Memo
Novartis - Strategy Memo
 
Strategic Management presentation for a Pharmaceutical Industry
Strategic Management presentation for a Pharmaceutical IndustryStrategic Management presentation for a Pharmaceutical Industry
Strategic Management presentation for a Pharmaceutical Industry
 
SUN PHARMA & PHARMA INDUSTRY 2015
SUN PHARMA &  PHARMA INDUSTRY 2015SUN PHARMA &  PHARMA INDUSTRY 2015
SUN PHARMA & PHARMA INDUSTRY 2015
 
cipla and sun pharma
cipla and sun pharmacipla and sun pharma
cipla and sun pharma
 
Pharmaceutical Marketing Strategy
Pharmaceutical Marketing StrategyPharmaceutical Marketing Strategy
Pharmaceutical Marketing Strategy
 
Brand plan for 2010 glycomet (us vitamin) - mitesh shah
Brand plan for 2010   glycomet (us vitamin) - mitesh shahBrand plan for 2010   glycomet (us vitamin) - mitesh shah
Brand plan for 2010 glycomet (us vitamin) - mitesh shah
 
Pfizer
PfizerPfizer
Pfizer
 
Glaxosmithkline portfolio
Glaxosmithkline portfolioGlaxosmithkline portfolio
Glaxosmithkline portfolio
 
Competitive advantage and strategy formulation process
Competitive advantage and strategy formulation processCompetitive advantage and strategy formulation process
Competitive advantage and strategy formulation process
 
Merck: Global Health and Access to Medicines
Merck: Global Health and Access to  MedicinesMerck: Global Health and Access to  Medicines
Merck: Global Health and Access to Medicines
 
Pfizer company analysis
Pfizer company analysisPfizer company analysis
Pfizer company analysis
 
Merck powerpoint
Merck powerpointMerck powerpoint
Merck powerpoint
 
GlaxoSmithKline
GlaxoSmithKlineGlaxoSmithKline
GlaxoSmithKline
 
Supply Chain Management Glenmark Pharma
Supply Chain Management Glenmark PharmaSupply Chain Management Glenmark Pharma
Supply Chain Management Glenmark Pharma
 
Pharma Plan Presentation Powerpoint
Pharma Plan Presentation PowerpointPharma Plan Presentation Powerpoint
Pharma Plan Presentation Powerpoint
 
Case Study Analysis on GlaxoSmithkline
Case Study Analysis on GlaxoSmithklineCase Study Analysis on GlaxoSmithkline
Case Study Analysis on GlaxoSmithkline
 
Glaxo smith-kline-presentation
Glaxo smith-kline-presentationGlaxo smith-kline-presentation
Glaxo smith-kline-presentation
 
Abbott
AbbottAbbott
Abbott
 

Andere mochten auch

Merck & Co Presentation
Merck & Co PresentationMerck & Co Presentation
Merck & Co Presentationtylerrives
 
Business Report on Pfizer
Business Report on PfizerBusiness Report on Pfizer
Business Report on PfizerAileen Marshall
 
About Pfizer Company
About Pfizer CompanyAbout Pfizer Company
About Pfizer Companyindira 7
 
Pfizer-Strategic Management Case
Pfizer-Strategic Management CasePfizer-Strategic Management Case
Pfizer-Strategic Management CaseSanjaya Sanjaya
 
Taming the ever-evolving Compliance Beast : Lessons learnt at LinkedIn [Strat...
Taming the ever-evolving Compliance Beast : Lessons learnt at LinkedIn [Strat...Taming the ever-evolving Compliance Beast : Lessons learnt at LinkedIn [Strat...
Taming the ever-evolving Compliance Beast : Lessons learnt at LinkedIn [Strat...Shirshanka Das
 

Andere mochten auch (7)

Merck & Co Presentation
Merck & Co PresentationMerck & Co Presentation
Merck & Co Presentation
 
Business Report on Pfizer
Business Report on PfizerBusiness Report on Pfizer
Business Report on Pfizer
 
About Pfizer Company
About Pfizer CompanyAbout Pfizer Company
About Pfizer Company
 
Pfizer-Strategic Management Case
Pfizer-Strategic Management CasePfizer-Strategic Management Case
Pfizer-Strategic Management Case
 
Pfizer case study
Pfizer case studyPfizer case study
Pfizer case study
 
merck and co. inc
merck and co. incmerck and co. inc
merck and co. inc
 
Taming the ever-evolving Compliance Beast : Lessons learnt at LinkedIn [Strat...
Taming the ever-evolving Compliance Beast : Lessons learnt at LinkedIn [Strat...Taming the ever-evolving Compliance Beast : Lessons learnt at LinkedIn [Strat...
Taming the ever-evolving Compliance Beast : Lessons learnt at LinkedIn [Strat...
 

Ähnlich wie Merck presentation.

Vaccine industry overview
Vaccine industry overviewVaccine industry overview
Vaccine industry overviewNaveen Kumar
 
FREE REPORT: PROGENICS PHARMACEUTICALS, INC
FREE REPORT: PROGENICS PHARMACEUTICALS, INCFREE REPORT: PROGENICS PHARMACEUTICALS, INC
FREE REPORT: PROGENICS PHARMACEUTICALS, INCBret Jensen
 
Pharma Uptoday Monthly Magazine - Volume 11, Issue Feb 2015
Pharma Uptoday Monthly Magazine - Volume 11, Issue Feb 2015Pharma Uptoday Monthly Magazine - Volume 11, Issue Feb 2015
Pharma Uptoday Monthly Magazine - Volume 11, Issue Feb 2015Sathish Vemula
 
Pushkar Vartak - DNA Vaccine Market Research Poster v4
Pushkar Vartak - DNA Vaccine Market Research Poster  v4Pushkar Vartak - DNA Vaccine Market Research Poster  v4
Pushkar Vartak - DNA Vaccine Market Research Poster v4Pushkar Vartak
 
VIAGRA: Wonder Drug or Ethical Irresponsibility?
VIAGRA: Wonder Drug or Ethical Irresponsibility?VIAGRA: Wonder Drug or Ethical Irresponsibility?
VIAGRA: Wonder Drug or Ethical Irresponsibility?tofugirl
 
2018/09 – BoA-ML HC Conference
2018/09 – BoA-ML HC Conference2018/09 – BoA-ML HC Conference
2018/09 – BoA-ML HC ConferenceSanofi
 
Generic prescribing akmccc
Generic prescribing  akmcccGeneric prescribing  akmccc
Generic prescribing akmcccOrgonic Baba
 
Pharma Uptoday Monthly Magazine - Volume 19; issue: Oct 2015
Pharma Uptoday Monthly Magazine - Volume 19; issue: Oct 2015Pharma Uptoday Monthly Magazine - Volume 19; issue: Oct 2015
Pharma Uptoday Monthly Magazine - Volume 19; issue: Oct 2015Sathish Vemula
 
Report on Gilead Sciences
Report on Gilead SciencesReport on Gilead Sciences
Report on Gilead SciencesRandy Acosta
 
Genetic Technologies Investor Presentation September 2022
Genetic Technologies Investor Presentation September 2022Genetic Technologies Investor Presentation September 2022
Genetic Technologies Investor Presentation September 2022RedChip Companies, Inc.
 
Genetic Technologies Presentation - January 2021
Genetic Technologies Presentation -  January 2021Genetic Technologies Presentation -  January 2021
Genetic Technologies Presentation - January 2021RedChip Companies, Inc.
 
Pharmacovigilance System in Pakistan
Pharmacovigilance System in PakistanPharmacovigilance System in Pakistan
Pharmacovigilance System in PakistanCepal & Co.
 
One mans supergeneric is anothers life cycle management
One mans supergeneric is anothers life cycle managementOne mans supergeneric is anothers life cycle management
One mans supergeneric is anothers life cycle managementMalcolm Ross
 
Pharmacovigilance in Focus by Dr.Prashant, Cipla
Pharmacovigilance in Focus by Dr.Prashant, CiplaPharmacovigilance in Focus by Dr.Prashant, Cipla
Pharmacovigilance in Focus by Dr.Prashant, CiplaUntil ROI
 
Group4padgett&becoatm6a1
Group4padgett&becoatm6a1Group4padgett&becoatm6a1
Group4padgett&becoatm6a1Stephen Padgett
 
Group4 padgett&becoatm6a1
Group4 padgett&becoatm6a1Group4 padgett&becoatm6a1
Group4 padgett&becoatm6a1Henry Becoat
 

Ähnlich wie Merck presentation. (20)

Ranvver sharma ppt
Ranvver sharma pptRanvver sharma ppt
Ranvver sharma ppt
 
Vaccine industry overview
Vaccine industry overviewVaccine industry overview
Vaccine industry overview
 
FREE REPORT: PROGENICS PHARMACEUTICALS, INC
FREE REPORT: PROGENICS PHARMACEUTICALS, INCFREE REPORT: PROGENICS PHARMACEUTICALS, INC
FREE REPORT: PROGENICS PHARMACEUTICALS, INC
 
Pharma Uptoday Monthly Magazine - Volume 11, Issue Feb 2015
Pharma Uptoday Monthly Magazine - Volume 11, Issue Feb 2015Pharma Uptoday Monthly Magazine - Volume 11, Issue Feb 2015
Pharma Uptoday Monthly Magazine - Volume 11, Issue Feb 2015
 
Pushkar Vartak - DNA Vaccine Market Research Poster v4
Pushkar Vartak - DNA Vaccine Market Research Poster  v4Pushkar Vartak - DNA Vaccine Market Research Poster  v4
Pushkar Vartak - DNA Vaccine Market Research Poster v4
 
VIAGRA: Wonder Drug or Ethical Irresponsibility?
VIAGRA: Wonder Drug or Ethical Irresponsibility?VIAGRA: Wonder Drug or Ethical Irresponsibility?
VIAGRA: Wonder Drug or Ethical Irresponsibility?
 
1 1 Innovation Wild
1 1 Innovation Wild1 1 Innovation Wild
1 1 Innovation Wild
 
Bayer(benazir)
Bayer(benazir)Bayer(benazir)
Bayer(benazir)
 
2018/09 – BoA-ML HC Conference
2018/09 – BoA-ML HC Conference2018/09 – BoA-ML HC Conference
2018/09 – BoA-ML HC Conference
 
Generic prescribing akmccc
Generic prescribing  akmcccGeneric prescribing  akmccc
Generic prescribing akmccc
 
Pharma Uptoday Monthly Magazine - Volume 19; issue: Oct 2015
Pharma Uptoday Monthly Magazine - Volume 19; issue: Oct 2015Pharma Uptoday Monthly Magazine - Volume 19; issue: Oct 2015
Pharma Uptoday Monthly Magazine - Volume 19; issue: Oct 2015
 
Report on Gilead Sciences
Report on Gilead SciencesReport on Gilead Sciences
Report on Gilead Sciences
 
Genetic Technologies Investor Presentation September 2022
Genetic Technologies Investor Presentation September 2022Genetic Technologies Investor Presentation September 2022
Genetic Technologies Investor Presentation September 2022
 
Genetic Technologies Presentation - January 2021
Genetic Technologies Presentation -  January 2021Genetic Technologies Presentation -  January 2021
Genetic Technologies Presentation - January 2021
 
Pharmacovigilance System in Pakistan
Pharmacovigilance System in PakistanPharmacovigilance System in Pakistan
Pharmacovigilance System in Pakistan
 
One mans supergeneric is anothers life cycle management
One mans supergeneric is anothers life cycle managementOne mans supergeneric is anothers life cycle management
One mans supergeneric is anothers life cycle management
 
Pharma 2014: Rework, Renaissance or Ragnarök?
Pharma 2014: Rework, Renaissance or Ragnarök?Pharma 2014: Rework, Renaissance or Ragnarök?
Pharma 2014: Rework, Renaissance or Ragnarök?
 
Pharmacovigilance in Focus by Dr.Prashant, Cipla
Pharmacovigilance in Focus by Dr.Prashant, CiplaPharmacovigilance in Focus by Dr.Prashant, Cipla
Pharmacovigilance in Focus by Dr.Prashant, Cipla
 
Group4padgett&becoatm6a1
Group4padgett&becoatm6a1Group4padgett&becoatm6a1
Group4padgett&becoatm6a1
 
Group4 padgett&becoatm6a1
Group4 padgett&becoatm6a1Group4 padgett&becoatm6a1
Group4 padgett&becoatm6a1
 

Merck presentation.

Hinweis der Redaktion

  1. About Merck
Merck is a global research-driven pharmaceutical company dedicated to putting patients first.Merck had originally founded in 1668 in Germany, and established in 1891 in U.S.A. and in its early years, we were selling medicines. Merck currently discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs.  The Company devotes extensive efforts to increase access to medicines through far-reaching programs that donate our medicines but help deliver them to the people who need them.
  2. there are many programs in our company that help us to deliver medicines to people who need them, and these are some of them.in Merck Patient Assistance Program, we provided free medicines to whocould not afford them. Medicines for chronic conditions that affect millions – like diabetes, asthma and high blood pressure.In 2008, approximately 1.5 million prescriptions were filled under the Merck Patient Assistance Program. Merck Prescription Discount Program for the uninsured people, they can save from 15 to 20 % off and it is easy to access by filling a 1 page application. we have a research program for HIV, Merck and University of Cape Town and Tertiary School of Business Administration, have been in partnership since 2004 to implement an HIV and AIDS curriculum for students in underserved communities in Cape Town, South Africa.Merck Medical Outreach Program. Founded in 1958, and it is one of the ways Merck helps to expand access to medicines and vaccines, especially in the developing world.
  3. Merck has made an initial contribution of $450,000 to assist relief efforts through many organizations such as project HOPE and the American Red Cross.We also are donating needed medicines through our Merck Medical Outreach Program.we also allowing our employees who are licensed health professionals or allied health services providers, to take one paid week and participate on the ground in Haiti with non-profit organizations
  4. Our products: we cover many areas in pharmaceutical industry from vaccines, prescription products, Consumer Products and Animal Health.we have 15 different vaccines , 40 prescription products and 17 Consumer products and we offer a broad choice of vaccines, anti-infective and anti parasitic drugs for animal health.
  5. as we mentioned before about drug discovery stages, after we get the approval from (FDA), we can proceed with other procedures such as piblishing, manufacturing and marketing and sales as you can see the value chain of the industry.
  6. Today’s Merck: Merck and Schering-Plough recently merged to create a new company. Today, we are the second-largest pharmaceutical company in the world by market share. We also are a global leader in consumer products and animal care. Both Merck and Schering-Plough have a long and rich history of working in pharmaceutical industry. and we are enthusiastic about the future of this new companyour merger will helps improve research and development productivity and offer cost savings opportunities and new products to help companies manage through lean times. what happened is the CEO made a hard decision, to eliminate some of the duplication jobs. “We have taken the best from both companies, from a process standpoint and a people standpoint.” the CEO Clark statedBiotech medicationsLast December, Merck launched a new division called Merck BioVentures to make both new and follow-on, generic, biotech drugs. They are starting to show up in Europe, but are not yet allowed in the U.S.This is one of areas that Merck is targeting for growth. "At Merck we continue to execute on our strategy of expanding our biopharmaceutical expertise and manufacturing capacity.AcquisitionAvecia Biologics is a contract manufacturing organization with specific expertise in microbial-derived biologics. Financial details of the transaction were not disclosed.
  7. Certain of the Company’s major products are going to lose patent protection in the near futureThe Company is dependent on its patent rights, and if its patent rights are invalidated, the business would be adversely affected. another fact that The Company’s products, including products in development, can not be marketed unless the Company obtains and maintains regulatory approval.
  8. Roberto gallo, Litton industry, Nixon, Kissinger, bio weappon-
  9. Roberto gallo, Litton industry, Nixon, Kissinger, bio weappon-